During the last session, ProQR Therapeutics N.V (NASDAQ:PRQR)’s traded shares were 0.32 million, with the beta value of the company hitting 0.25. At the end of the trading day, the stock’s price was $3.73, reflecting an intraday gain of 6.57% or $0.23. The 52-week high for the PRQR share is $4.62, that puts it down -23.86 from that peak though still a striking 69.71% gain since the share price plummeted to a 52-week low of $1.13. The company’s market capitalization is $384.95M, and the average intraday trading volume over the past 10 days was 1.39 million shares, and the average trade volume was 1.25 million shares over the past three months.

ProQR Therapeutics N.V (PRQR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.33. PRQR has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.12.

ProQR Therapeutics N.V (NASDAQ:PRQR) trade information

ProQR Therapeutics N.V (PRQR) registered a 6.57% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.57% in intraday trading to $3.73, hitting a weekly high. The stock’s 5-day price performance is 7.80%, and it has moved by 104.95% in 30 days. Based on these gigs, the overall price performance for the year is 221.55%. The short interest in ProQR Therapeutics N.V (NASDAQ:PRQR) is 0.13 million shares and it means that shorts have 0.83 day(s) to cover.

The consensus price target of analysts on Wall Street is $3.75, which implies an increase of 0.53% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $5 respectively. As a result, PRQR is trading at a discount of -34.05% off the target high and 46.38% off the low.

ProQR Therapeutics N.V (PRQR) estimates and forecasts

Statistics show that ProQR Therapeutics N.V has outperformed its competitors in share price, compared to the industry in which it operates. ProQR Therapeutics N.V (PRQR) shares have gone up 85.57% during the last six months, with a year-to-date growth rate more than the industry average at 18.42% against 17.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -50.00% this quarter and then drop -12.50% in the quarter after that. In the rating firms’ projections, revenue will increase 176.40% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 12.05M as predicted by 5 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 5.54M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.49M and 6.75M respectively. In this case, analysts expect current quarter sales to grow by 709.80% and then drop by -17.90% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 21.74%. While earnings are projected to return 3.76% in 2024.

PRQR Dividends

ProQR Therapeutics N.V is due to release its next quarterly earnings on 2024-Aug-08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

The next largest institutional holding, with 3.63 million shares, is of ADAGE CAPITAL PARTNERS GP, L.L.C.’s that is approximately 4.4446% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $6.02 million.